Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and three have issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $40.7778.

A number of analysts have weighed in on STRO shares. Citizens Jmp raised their price objective on shares of Sutro Biopharma from $35.00 to $41.00 and gave the company a “market outperform” rating in a research note on Thursday, April 23rd. Wall Street Zen upgraded shares of Sutro Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Truist Financial upgraded shares of Sutro Biopharma to a “strong-buy” rating in a research note on Monday, May 4th. Lifesci Capital upgraded shares of Sutro Biopharma to a “strong-buy” rating in a research note on Friday, May 1st. Finally, Citigroup restated an “outperform” rating on shares of Sutro Biopharma in a research note on Friday, April 17th.

Institutional Trading of Sutro Biopharma

A number of large investors have recently made changes to their positions in STRO. Invesco Ltd. grew its stake in shares of Sutro Biopharma by 137.8% in the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after acquiring an additional 53,390 shares during the period. AQR Capital Management LLC grew its stake in shares of Sutro Biopharma by 1,052.8% in the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after acquiring an additional 1,206,330 shares during the period. Strs Ohio bought a new stake in shares of Sutro Biopharma in the first quarter worth approximately $99,000. Marshall Wace LLP bought a new stake in shares of Sutro Biopharma in the second quarter worth approximately $166,000. Finally, Cerity Partners LLC grew its stake in shares of Sutro Biopharma by 169.9% in the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock worth $75,000 after acquiring an additional 66,372 shares during the period. 96.99% of the stock is currently owned by institutional investors.

Sutro Biopharma Stock Performance

NASDAQ:STRO opened at $39.31 on Thursday. The firm has a market cap of $651.37 million, a P/E ratio of -1.51 and a beta of 1.63. Sutro Biopharma has a fifty-two week low of $6.74 and a fifty-two week high of $41.88. The firm has a 50-day simple moving average of $27.67 and a two-hundred day simple moving average of $17.53.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.